GLP1_NEW
Dulaglutide with macupatide 1.5 to 20 mg injection once weekly
DULAMACU_SC_1p5-20MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 3.95 (0.15 to 150) | 0.23 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 9.32 (0.64 to 245) | 0.17 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.08 (0.15 to 5.24) | 0.72 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.05 (0.26 to 14.42) | 0.55 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.48 (0.77 to 8.23) | 0.33 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.64 (0.05 to 4.81) | 0.71 |